Evas Therapeutics Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

Evas Therapeutics General Information

Description

Developer of novel therapies for debilitating diseases associated with tissue injury and cell death. The company develops therapy for pharmacotherapy of various debilitating diseases including acute myocardial infarction, stroke, unstable atherosclerotic diseases, transplant rejection, hemodialysis vascular access failure and neurodegenerative diseases, enabling physicians to cure diseases.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 613 Huntley Heights Drive
  • Ballwin, MO 63021
  • United States
+1 (636) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Evas Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business 01-Aug-2019 Completed Out of Business
2. Grant 01-Jan-2018 00.000 Completed Startup
1. Accelerator/Incubator Completed Startup
To view Evas Therapeutics’s complete valuation and funding history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »